Federated Investors Inc. PA grew its holdings in Enzo Biochem, Inc. (NYSE:ENZ) by 8.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,006 shares of the medical research company’s stock after purchasing an additional 9,762 shares during the quarter. Federated Investors Inc. PA owned about 0.26% of Enzo Biochem worth $1,314,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. State Board of Administration of Florida Retirement System lifted its stake in shares of Enzo Biochem by 386.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 94,746 shares of the medical research company’s stock valued at $1,046,000 after purchasing an additional 75,272 shares during the period. Marshall Wace North America L.P. lifted its stake in shares of Enzo Biochem by 159.5% in the 2nd quarter. Marshall Wace North America L.P. now owns 76,375 shares of the medical research company’s stock valued at $840,000 after purchasing an additional 46,943 shares during the period. Legal & General Group Plc lifted its stake in shares of Enzo Biochem by 10.6% in the 2nd quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 1,022 shares during the period. Evermore Global Advisors LLC lifted its stake in shares of Enzo Biochem by 7.3% in the 2nd quarter. Evermore Global Advisors LLC now owns 3,555,233 shares of the medical research company’s stock valued at $39,250,000 after purchasing an additional 242,441 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Enzo Biochem by 7.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 221,166 shares of the medical research company’s stock valued at $2,442,000 after purchasing an additional 14,719 shares during the period. 62.85% of the stock is currently owned by institutional investors.

Enzo Biochem, Inc. (NYSE ENZ) opened at 10.89 on Thursday. Enzo Biochem, Inc. has a 52 week low of $4.88 and a 52 week high of $12.04. The firm has a market capitalization of $505.37 million, a P/E ratio of 15.27 and a beta of 0.92. The stock has a 50 day moving average price of $11.12 and a 200-day moving average price of $9.65.

COPYRIGHT VIOLATION NOTICE: “Enzo Biochem, Inc. (ENZ) Stake Lifted by Federated Investors Inc. PA” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/14/enzo-biochem-inc-enz-stake-lifted-by-federated-investors-inc-pa.html.

A number of research analysts have recently issued reports on ENZ shares. Zacks Investment Research raised Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, June 20th. BidaskClub raised Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.